Appropriately switching your eligible NVAF patients
from VKA to a DOAC during COVID-19

As you know, your elderly patients, particularly those with AF and other underlying health conditions, are
at significantly increased risk of health-related complications from COVID-19.*,2,3

You can continue to provide the stroke protection your
patients with NVAF need, while reducing their risk
of exposure through social distancing.4

Frequent INR monitoring is a required component
of managing patients on warfarin.5

Unfortunately, these frequent visits to HCPs
mean your patients are less able to maintain
social distancing.

Switching appropriate patients from warfarin to a DOAC may
be considered to avoid regular blood tests for INR monitoring.
Government (NHS England) guidance endorsed by:6

  • BSH
  • RCGP
  • RPS
  • UKCPA
  • PCPA
  • PCCS

“If a DOAC is an option consider switching
in line with patient’s informed consent.”

BSH Guidance on COVID-197

With a DOAC, you can offer your patient:1,8–10

  • No ongoing routine monitoring of coagulation
    parameters or blood testing requirements
  • A regular, fixed-dose prescribing regime
  • Fewer drug interactions vs warfarin

During this crisis, we’ll do everything we can to help protect
what matters for you and your NVAF patients